Roche Applied Science will supply Eli Lilly and SeqWright with technologies to identify genetic variants associated with various psychiatric diseases. SeqWright will utilize NimbleGen sequence capture technology to selectively enrich approximately 40 megabases of the human genome. This will then be sequenced using 454 Life Sciences’ Genome Sequencer FLX System.

“Just a year ago, it would have been impossible to imagine how we could selectively sequence such a large portion of the human genome in such a fast and cost-effective manner,” remarks Brian Edmonds, Ph.D., research advisor, global external research and development, Eli Lilly.  “Our goal at Lilly is to improve the outcomes of individual patients; increasing the speed at which we begin to understand the basis of disease is critical to improving those outcomes. We are participating in this collaboration as a way to better examine the root causes of various psychiatric diseases.”

Previous articleNanotechnology Advances
Next articleDxS to Provide a Companion Diagnostic for AstraZeneca’s NSCLC Drug